Saxenda (Liraglutide 3 mg) for Adults 65 and Older: School, Activity, and Daily Life Considerations

Print or save as PDF

What is the Saxenda dose schedule for adults?

The adult Saxenda schedule starts at 0.6 mg daily and increases weekly to 3 mg by week 5 (0.6, 1.2, 1.8, 2.4, then 3 mg) [1]. In the label, 3 mg is the recommended adult dose and lower doses are for titration only, with discontinuation advised if 3 mg is not tolerated [1].

If a dose increase is not tolerated during escalation, the label says to consider delaying escalation by about one additional week [1]. Weight is evaluated 16 weeks after starting, and the label says to discontinue if less than 4% of baseline body weight has been lost [1].

What did the main trial show?

SCALE enrolled 3,731 adults without type 2 diabetes and with BMI at least 30, or at least 27 with dyslipidemia or hypertension [5]. Mean age was 45.1 years, mean weight was 106.2 kg, and 78.5% were women [5]. At 56 weeks, liraglutide 3 mg plus lifestyle counseling produced a mean loss of 8.4 kg versus 2.8 kg with placebo; 63.2% versus 27.1% lost at least 5%, and 33.1% versus 10.6% lost more than 10% [5].

The SCALE trial reported weight outcomes, not an exercise prescription or a geriatric muscle-function outcome [5].

How does Saxenda fit a daily activity schedule?

Saxenda is injected subcutaneously in the abdomen, thigh or upper arm once daily at any time of day, without regard to meals [1]. Changing the injection site or the time of day does not require a dose adjustment [1].

If a dose is missed, the label says to resume with the next scheduled daily dose without doubling up; if more than 3 days have passed since the last dose, it says to restart at 0.6 mg and re-titrate [1]. The label's activity instruction is general: Saxenda is used in combination with a reduced-calorie diet and increased physical activity [1].

Which side effects are most likely to affect daily activity?

In the adult trials, nausea occurred in 39.3% on Saxenda vs 13.8% on placebo, diarrhea in 20.9% vs 9.9%, constipation in 19.4% vs 8.5%, vomiting in 15.7% vs 3.9%, fatigue in 7.5% vs 4.6%, and dizziness in 6.9% vs 5% [1]. About 68% vs 39% reported any gastrointestinal disorder, and nausea declined as treatment continued [1]. Adverse reactions led to discontinuation in 9.8% vs 4.3% [1].

The label warns about severe gastrointestinal adverse reactions and says Saxenda is not recommended in severe gastroparesis [1]. It also warns about acute kidney injury due to volume depletion and advises monitoring renal function in patients reporting reactions that could lead to volume depletion [1].

Does Saxenda change heart rate during daily life?

Saxenda increased resting heart rate by a mean of 2 to 3 bpm in adult trials [1]. A rise of more than 10 bpm at two consecutive visits occurred in 34% vs 19% on placebo, and at least one resting heart rate over 100 bpm occurred in 6% vs 4% [1]. The label says to monitor heart rate at regular intervals [1].

What about hypoglycemia with insulin or sulfonylureas?

The label warns that hypoglycemia can occur in adults when Saxenda is used with an insulin secretagogue such as a sulfonylurea or with insulin, and that severe hypoglycemia is possible [1]. In adults with type 2 diabetes taking a sulfonylurea, glucose below 54 mg/dL occurred in 28.2% on Saxenda vs 12.7% on placebo; sulfonylurea doses were cut 50% at the start of that trial [1]. The label says the risk may be lowered by reducing the dose of the sulfonylurea or insulin, and advises monitoring blood glucose before starting and during Saxenda treatment in type 2 diabetes [1].

How do oral medicines and procedures fit into daily life?

Saxenda delays gastric emptying and may affect absorption of oral medicines [1]. In clinical pharmacology trials, liraglutide did not affect the absorption of tested oral drugs to a clinically relevant degree, but the label advises monitoring for consequences of delayed absorption [1].

The label also warns about pulmonary aspiration during general anesthesia or deep sedation in patients receiving GLP-1 receptor agonists who undergo elective surgeries or procedures [1]. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with Saxenda, and the label says to discontinue Saxenda if one occurs [1].

What pancreatitis and gallbladder warnings matter after 65?

The label warns about acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, and says to discontinue Saxenda if pancreatitis is suspected [1]. Symptoms may include persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting [1].

In adult trials, cholelithiasis was reported in 2.2% vs 0.8% and cholecystitis in 0.8% vs 0.4% [1]. The label notes that substantial or rapid weight loss can increase the risk of gallstones [1].

What does this mean for muscle and function in older adults?

A review of sarcopenic obesity in adults 65 and older describes the overlap of excess fat and low muscle mass and lists calorie restriction, protein supplementation, and aerobic and resistance exercise as current treatment strategies [4]. It also describes weight-loss-induced complications relevant to clinical management [4].

A 2024 review of obesity drug treatment in older adults concluded that trials in this group need to measure muscle mass, bone quality and fat distribution before stronger recommendations can be made [2].